Myla D Goldman1, Melanie D Ward1, Robert W Motl2, David E Jones1, John H Pula3, Diego Cadavid4. 1. Department of Neurology, University of Virginia School of Medicine, Charlottesville, VA, USA. 2. Department of PT, School of Health Professions, University of Alabama at Birmingham, Birmingham, AL, USA. 3. College of Medicine at Peoria, University of Illinois, Peoria, IL, USA. 4. Biogen, Cambridge, MA, USA.
Abstract
BACKGROUND: The 12-item Multiple Sclerosis Walking Scale (12-MSWS) is a validated questionnaire which assessed walking function; it has been widely adopted in multiple sclerosis (MS) clinical research. OBJECTIVE: Identify and validate clinically meaningful 12-MSWS benchmarks in MS. METHODS: Cross-sectional study of 159 MS patients permitted identification of clinically meaningful 12-MSWS benchmarks based on their relationship to real-life anchors. Identified 12-MSWS benchmarks were then validated in a second population of 96 subjects using measures of ambulation, cognition, and patient-reported outcomes. RESULTS: 12-MSWS score of 0-24.99 was associated with working outside the home and assistance-free mobility; 25-49.99 was associated with gait disability and difficulty doing housework; 50-74.99 was associated with unemployment, government healthcare, cane use, and difficulty performing instrumental activities of daily living (IADLs); and 75-100 was associated with change in occupation due to walking, mobility impairment requiring bilateral assistance, and inability to perform IADLs. During the validation step, strong linear associations were identified between 12-MSWS benchmarks and other MS-related disability outcome measures, including ambulatory and non-ambulatory measures. CONCLUSION: We have identified clinically meaningful 12-MSWS benchmarks which define four groups differentiated by increasing levels of mobility impairment and associated loss of functional independence. These data provide insight into how 12-MSWS translate to meaningful functional limitations in MS.
BACKGROUND: The 12-item Multiple Sclerosis Walking Scale (12-MSWS) is a validated questionnaire which assessed walking function; it has been widely adopted in multiple sclerosis (MS) clinical research. OBJECTIVE: Identify and validate clinically meaningful 12-MSWS benchmarks in MS. METHODS: Cross-sectional study of 159 MS patients permitted identification of clinically meaningful 12-MSWS benchmarks based on their relationship to real-life anchors. Identified 12-MSWS benchmarks were then validated in a second population of 96 subjects using measures of ambulation, cognition, and patient-reported outcomes. RESULTS: 12-MSWS score of 0-24.99 was associated with working outside the home and assistance-free mobility; 25-49.99 was associated with gait disability and difficulty doing housework; 50-74.99 was associated with unemployment, government healthcare, cane use, and difficulty performing instrumental activities of daily living (IADLs); and 75-100 was associated with change in occupation due to walking, mobility impairment requiring bilateral assistance, and inability to perform IADLs. During the validation step, strong linear associations were identified between 12-MSWS benchmarks and other MS-related disability outcome measures, including ambulatory and non-ambulatory measures. CONCLUSION: We have identified clinically meaningful 12-MSWS benchmarks which define four groups differentiated by increasing levels of mobility impairment and associated loss of functional independence. These data provide insight into how 12-MSWS translate to meaningful functional limitations in MS.
Authors: Jacob J Sosnoff; Madeline Weikert; Deirdre Dlugonski; Douglas C Smith; Robert W Motl Journal: Gait Posture Date: 2011-04-30 Impact factor: 2.840
Authors: Rachel Brandstadter; Oluwasheyi Ayeni; Stephen C Krieger; Noam Y Harel; Miguel X Escalon; Ilana Katz Sand; Victoria M Leavitt; Michelle T Fabian; Korhan Buyukturkoglu; Sylvia Klineova; Claire S Riley; Fred D Lublin; Aaron E Miller; James F Sumowski Journal: Neurology Date: 2020-02-26 Impact factor: 9.910
Authors: Valerie J Block; Erica A Pitsch; Arpita Gopal; Chao Zhao; Mark J Pletcher; Gregory M Marcus; Jeffrey E Olgin; Jill Hollenbach; Riley Bove; Bruce A C Cree; Jeffrey M Gelfand Journal: J Neurol Date: 2021-08-17 Impact factor: 4.849
Authors: Valerie J Block; Riley Bove; Chao Zhao; Priya Garcha; Jennifer Graves; Andrew R Romeo; Ari J Green; Diane D Allen; Jill A Hollenbach; Jeffrey E Olgin; Gregory M Marcus; Mark J Pletcher; Bruce A C Cree; Jeffrey M Gelfand Journal: JAMA Netw Open Date: 2019-03-01